XML 39 R30.htm IDEA: XBRL DOCUMENT
v3.23.2

Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details) € in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | ---
Jun. 30, 2023 EUR (€) | Jun. 30, 2022 EUR (€) | Jun. 30, 2023 EUR (€) | Jun. 30, 2022 EUR (€) | Jun. 30, 2023 USD ($) | Dec. 31, 2022 EUR (€)
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Upfront and milestones payments included in contract liabilities | € 98,763 |  | € 98,763 |  |  | € 107,308
GSK |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Upfront and milestone payments | 205,000 |  | 205,000 |  |  |
Upfront and milestones payments included in contract liabilities | 95,307 |  | 95,307 |  |  | 102,804
CRISPR |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Upfront and milestone payments | 2,524 |  | 2,524 |  | $ 3,000 |
Upfront and milestones payments included in contract liabilities | 775 |  | 775 |  |  | 929
Genmab |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Upfront and milestone payments | 8,937 |  | 8,937 |  | $ 10,000 |
Upfront and milestones payments included in contract liabilities | 2,681 |  | 2,681 |  |  | € 3,575
Minimum | GSK |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Upfront and milestone payments | 10,000 |  | 10,000 |  |  |
Research services combined with an IP license |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Revenue recognized from upfront and milestones payments | 4,397 | € 13,575 | 8,545 | € 31,818 |  |
Research services combined with an IP license | GSK |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Revenue recognized from upfront and milestones payments | 3,873 | 13,051 | 7,496 | 30,769 |  |
Research services combined with an IP license | CRISPR |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Revenue recognized from upfront and milestones payments | 77 | 77 | 155 | 155 |  |
Research services combined with an IP license | Genmab |  |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |  |
Revenue recognized from upfront and milestones payments | € 447 | € 447 | € 894 | € 894 |  |

X
- Definition Represents of disclosure of notes to the consolidated financial statements. + References No definition available. + Details
Name: | cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems
Namespace Prefix: | cvac_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of upfront payments of the company included in contract liabilities. + References No definition available. + Details
Name: | cvac_UpfrontPaymentsIncludedInContractLiabilities
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of upfront payments received or receivable by the company. + References No definition available. + Details
Name: | cvac_UpfrontPaymentsReceivedOrReceivable
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2022-03-24 -Paragraph 116 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_b&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_CrisprMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GenmabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |